Physician profile
Kenneth Sandock
NPI 1841251733
$2,168.35
in general payments reported to CMS, 2019-2025
25 companies · $437 in 2025
The $437 reported for 2025 was more than what 76% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $164 · 2021: $147 · 2022: $244 · 2023: $409 · 2024: $414 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,259.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $512.79 | 2019-2023 | Lumakras, Blincyto, Kyprolis |
| Merck Sharp & Dohme LLC | $330.60 | 2020-2025 | Lynparza, Keytruda |
| Incyte Corporation | $213.61 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Regeneron Healthcare Solutions, INC. | $155.17 | 2023-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $141.35 | 2019-2023 | |
| Blueprint Medicines Corporation | $102.20 | 2023-2025 | Ayvakit, Gavreto |
| Takeda Pharmaceuticals U.S.A., INC. | $92.16 | 2024-2025 | Fruzaqla, Alunbrig |
| Janssen Biotech, INC. | $62.34 | 2023-2024 | Rybrevant |
| Genentech USA, INC. | $60.41 | 2024-2025 | Itovebi, Rozlytrek, Alecensa |
| Seagen INC. | $54.38 | 2022-2023 | Adcetris |
| Astrazeneca Pharmaceuticals LP | $54.05 | 2020-2025 | Imfinzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.90 | 2025 | |
| Pfizer INC. | $41.03 | 2024-2025 | |
| Lilly USA, LLC | $40.24 | 2022-2023 | Jaypirca, Retevmo, Verzenio |
| Karyopharm Therapeutics INC. | $36.61 | 2023-2024 | Xpovio |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $29.32 | 2025 | Datroway |
| Novartis Pharmaceuticals Corporation | $27.74 | 2025 | |
| Beigene USA, INC. | $27.61 | 2024 | Brukinsa |
| Sobi, INC | $24.29 | 2024 | |
| Genzyme Corporation | $21.74 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $20.29 | 2020 | |
| Myovant Sciences INC. | $19.67 | 2021 | |
| Adaptive Biotechnologies Corporation | $17.30 | 2024 | Clonoseq |
| Dova Pharmaceuticals | $15.35 | 2019 | |
| Eusa Pharma (US) LLC | $15.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Sandock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.